Duloxetine
Generic Name: duloxetine
Brand Names:
Duloxetine
Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI) available as delayed-release capsules in 20 mg, 30 mg, 40 mg, and 60 mg strengths.
Overview
Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI) available as delayed-release capsules in 20 mg, 30 mg, 40 mg, and 60 mg strengths.
Uses
Indicated for treatment of major depressive disorder in adults, generalized anxiety disorder in adults and pediatric patients 7+, diabetic peripheral neuropathic pain in adults, fibromyalgia in adults and pediatric patients 13+, and chronic musculoskeletal pain in adults.
Dosage
Varies by indication; typically 30-60 mg once daily orally. Swallow whole; do not crush, chew, or open capsule.
Side Effects
Most common include nausea (23%), dry mouth (13%), somnolence (10%), constipation (9%), dizziness (9%), decreased appetite (7%).
Interactions
Contraindicated with MAOIs intended to treat psychiatric disorders due to increased risk of serotonin syndrome.
Warnings
BOXED WARNING: Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. Hepatotoxicity warnings, orthostatic hypotension risks, serotonin syndrome alerts, bleeding risk increases, severe skin reactions, discontinuation syndrome.
Frequently Asked Questions
What is Duloxetine used for?▼
Indicated for treatment of major depressive disorder in adults, generalized anxiety disorder in adults and pediatric patients 7+, diabetic peripheral neuropathic pain in adults, fibromyalgia in adults and pediatric patients 13+, and chronic musculoskeletal pain in adults.
What are the side effects of Duloxetine?▼
Most common include nausea (23%), dry mouth (13%), somnolence (10%), constipation (9%), dizziness (9%), decreased appetite (7%).
What are the important warnings for Duloxetine?▼
BOXED WARNING: Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. Hepatotoxicity warnings, orthostatic hypotension risks, serotonin syndrome alerts, bleeding risk increases, severe skin reactions, discontinuation syndrome.
Related Medications
Palivizumab
palivizumab
Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]
11 DESCRIPTION Palivizumab is a humanized monoclonal antibody (IgG1κ) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of RSV. Palivizumab is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the V H genes Cor and Cess.
Deferoxamine Mesylate
deferoxamine mesylate
11 DESCRIPTION Deferoxamine mesylate for injection USP, is an iron-chelating agent, available in vials for injection via intramuscular, subcutaneous, and intravenous administration. Deferoxamine mesylate for injection USP, is supplied as vials containing 500 mg and 2 grams of deferoxamine mesylate USP (corresponding to 426.82 mg and 1.707 grams of deferoxamine as free base) in sterile, lyophilized form.
Cefepime Hydrochloride Oral Grade
cefepime hydrochloride oral grade
Dosage form: POWDER. Active ingredients: CEFEPIME HYDROCHLORIDE (1 kg/kg). Category: BULK INGREDIENT.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.